Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
446.00    -1.50 (-0.34%)
Bid:
445.00
Ask:
450.00
Spread: 5.00 (1.124%)
Market Cap: £219.35m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Director/PDMR Shareholding

22 Dec 2017 12:27

RNS Number : 2540A
Zotefoams PLC
22 December 2017
 

Zotefoams plc (the 'Company')

 

Directors' Shareholdings

 

On 20 December 2017, David Stirling, Group CEO, exercised his option under the Company's Approved Share Option Plan over 28,116 Ordinary Shares of 5p ('Shares') each in the capital of the Company at an exercise price of £1.067 per share. Mr Stirling sold all the Shares on 20 December 2017 at a price of £4.55 per share.

 

The Company was notified on 20 December 2017 that Mr Douglas Robertson, a Non-Executive Director of the Company, bought 5,416 Ordinary shares of 5p each in the Company on 20 December 2017 at a price of £4.59 per share.

 

Following this purchase, Mr Robertson is interested in 5,416 Ordinary Shares, representing just over 0.01% of the Company's issued share capital. Mr Stirling's shareholding remains unchanged.

 

The Notification of Dealing Forms can be found below.

 

This notification is made in accordance with the Market Abuse Regulation.

 

Enquiries:

James Kindell

Company Secretary

Zotefoams plc

 

22 December 2017

 

020 8664 1600

 

About Zotefoams plc:

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology. Using a unique manufacturing process with environmentally friendly nitrogen expansion, Zotefoams produces and sells lightweight AZOTE® polyolefin and ZOTEK® high-performance foams for diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. In addition, Zotefoams owns and licenses patented MuCell® microcellular foam technology, developed specifically for extrusion applications, from a base in Massachusetts, USA to customers worldwide.

 

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky and Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT®).

 

www.zotefoams.com

 

AZOTE®, ZOTEK®, T-FIT® are registered trademarks of Zotefoams plc

MuCell® is a registered trademark of Trexel Inc.

 

 

ZOTEFOAMS PLC

DEALING NOTIFICATION FORMFOR USE BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND THEIR CLOSELY ASSOCIATED PERSONS

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: David Stirling

2.

Reason for the notification

a)

Position/status: Group CEO

b)

Initial notification/Amendment: Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name: Zotefoams plc

b)

LEI: 213800B6P256B5XN8D32

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Ordinary shares of 5 pence each

Identification code: GB0009896605

b)

Nature of the transaction: Exercise of an option under the Approved Share Option Plan

c)

Price(s) and volume(s):

Price(s)

Volume(s)

£1.067

28,116

d)

Aggregated information:

 

Aggregate Price

Aggregate Volume

Aggregate Total

£1.067

28,116

£29,999.77

e)

Date of the transaction: 2017-12-20

f)

Place of the transaction: Outside a trading venue

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Ordinary shares of 5 pence each

Identification code: GB0009896605

b)

Nature of the transaction: Sale of shares from exercising an option under the Approved Share Option Plan.

c)

Price(s) and volume(s):

Price(s)

Volume(s)

£4.55

28,116

d)

Aggregated information:

 

Aggregate Price

Aggregate Volume

Aggregate Total

£4.55

28,116

£127,927.80

e)

Date of the transaction: 2017-12-20, 15:19:00

f)

Place of the transaction: XLON / BATE / CHIX / TRQX

 

ZOTEFOAMS PLC

DEALING NOTIFICATION FORMFOR USE BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND THEIR CLOSELY ASSOCIATED PERSONS

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Douglas Robertson

2.

Reason for the notification

a)

Position/status: Non-Executive Director

b)

Initial notification/Amendment: Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name: Zotefoams plc

b)

LEI: 213800B6P256B5XN8D32

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Ordinary shares of 5 pence each

Identification code: GB0009896605

b)

Nature of the transaction: Purchase of shares

c)

Price(s) and volume(s):

Price(s)

Volume(s)

£4.59

5,416

d)

Aggregated information:

 

Aggregate Price

Aggregate Volume

Aggregate Total

£4.59

5,416

£24,859.44

e)

Date of the transaction: 2017-12-20; 12.33.07

f)

Place of the transaction: XLON / BATE / CHIX / TRQX

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHEAAAAAAKXFFF
Date   Source Headline
11th Aug 20094:19 pmRNSHolding(s) in Company
10th Aug 200912:45 pmRNSHolding(s) in Company
4th Aug 20097:00 amRNSHalf Yearly Report
20th Jul 20091:42 pmRNSHolding(s) in Company
3rd Jul 20097:00 amRNSTrading Statement
17th Jun 20095:33 pmRNSHolding(s) in Company
5th Jun 200912:23 pmRNSDirector/PDMR Shareholding
19th May 200910:30 amRNSAnnual Information Update
12th May 200910:30 amRNSVoting Rights and Capital
7th May 20097:00 amRNSAGM Statement
7th Apr 200910:51 amRNSNotice of AGM
26th Mar 20097:00 amRNSAdditional Listing
18th Mar 20091:50 pmRNSDirector/PDMR Shareholding
16th Mar 20095:19 pmRNSDirector/PDMR Shareholding
10th Mar 20097:00 amRNSFinal Results
22nd Jan 200911:36 amRNSHolding(s) in Company
5th Jan 20091:19 pmRNSVoting Rights and Capital
19th Dec 20087:00 amRNSTrading Statement
12th Dec 200811:04 amRNSDirector/PDMR Shareholding
11th Dec 20082:20 pmRNSHolding(s) in Company
3rd Nov 20087:00 amRNSInterim Management Statement
30th Oct 20082:25 pmRNSAdditional Listing
14th Aug 20087:00 amRNSDirector/PDMR Shareholding
5th Aug 20087:00 amRNSInterim Results
9th Jul 20089:11 amRNSAcquires Stake
1st Jul 20087:00 amRNSTrading Update
5th Jun 20089:37 amRNSVoting rights and capital
23rd May 20085:38 pmRNSAnnual Information Update
8th May 20087:01 amRNSAGM Statement
14th Apr 20087:00 amRNSBlocklisting Interim Review
8th Apr 20086:07 pmRNSAdditional Listing
8th Apr 20088:18 amRNSNotice of AGM
25th Mar 20082:46 pmRNSDirector/PDMR Shareholding
4th Mar 20087:01 amRNSFinal Results
3rd Mar 20087:00 amRNSCustomer Achievement
1st Feb 20081:46 pmRNSTotal Voting Rights
21st Dec 20072:48 pmRNSDirectors' Shareholdings
26th Nov 200710:04 amRNSAdditional Listing
12th Nov 20077:01 amRNSDirector/PDMR Shareholding
7th Nov 20078:45 amRNSDirectors' Shareholdings
30th Oct 20072:55 pmRNSHolding in Company
19th Oct 20077:01 amRNSProduct Achievement
17th Oct 20079:32 amRNSBlocklisting Interim Review
5th Sep 200712:29 pmRNSHolding(s) in Company
28th Aug 20077:02 amRNSMarketing Alliance
7th Aug 20077:00 amRNSInterim Results
30th Jul 20074:45 pmRNSVoting rights & capital
12th Jul 20074:02 pmRNSDirectorate Change
29th Jun 200711:04 amRNSTrading Update
28th Jun 20072:23 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.